Provided by Tiger Fintech (Singapore) Pte. Ltd.

Chimerix

8.43
+0.0000
Post-market: 8.450.0200+0.24%19:55 EST
Volume:7.02M
Turnover:59.13M
Market Cap:758.16M
PE:-8.98
High:8.44
Open:8.42
Low:8.42
Close:8.43
Loading ...

Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

GlobeNewswire
·
10 Dec 2024

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
07 Dec 2024

Chimerix Price Target Maintained With a $6.00/Share by Wedbush

Dow Jones
·
19 Nov 2024

Chimerix’s Phase 2 Reassessment Boosts Buy Rating Amid Promising Data and Strong Financials

TIPRANKS
·
12 Nov 2024

Chimerix Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Nov 2024

Chimerix’s Dordaviprone Shows Promising Efficacy in H3 K27M-mutant Diffuse Glioma with $11 Price Target

TIPRANKS
·
11 Nov 2024

Press Release: Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting

Dow Jones
·
11 Nov 2024

Chimerix Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.
·
09 Nov 2024

Q3 2024 Chimerix Inc Earnings Call

Thomson Reuters StreetEvents
·
08 Nov 2024

Chimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial ...

GuruFocus.com
·
08 Nov 2024

Chimerix Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
07 Nov 2024

Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates

Zacks
·
07 Nov 2024

Chimerix Reports Q3 2024 Results and Study Progress

TIPRANKS
·
07 Nov 2024

Chimerix: Q3 Earnings Snapshot

Associated Press Finance
·
07 Nov 2024

BRIEF-Chimerix Reports Q3 2024 Financial Results And Provides Operational Update

Reuters
·
07 Nov 2024

Chimerix Q3 2024 GAAP EPS $(0.26) Misses $(0.24) Estimate, Sales $26.00K Miss $75.00K Estimate

Benzinga
·
07 Nov 2024